Reviewing the Journey of Cobenfy So Far & Future Directions for its Applications in Indications Beyond Schizophrenia
Time: 9:30 am
day: Day One
Details:
- Spotlighting the novel mechanism of action of Cobenfy and its selective muscarinic activation in the brain
- Demonstrating efficacy and safety in the ADEPT-2 Phase 3 Trial for Cobenfy in Alzheimer’s disease psychosis
- What are the opportunities for Cobenfy to be investigated for the treatment of psychosis in other dementias, bipolar, autism, and more?
